Member access

4-Traders Homepage  >  Shares  >  Euronext Paris  >  Sanofi    SAN   FR0000120578


Real-time Quote. Real-time Tradegate - 04/27 03:59:58 pm
96.138 EUR   +0.29%
03:04p SANOFI : ImmunoGen skids after disclosing drug development setbacks
07:59aDJSanofi SA 1Q 2015-- Forecast
04/24 SANOFI : Playing Safe With Your Food
News SummaryMost relevantAll newsSector news 

Sanofi: Tests Show Zaltrap Improves Colorectal Cancer Survival Rate

10/08/2012 | 01:44am US/Eastern

French drug company Sanofi SA (>> SANOFI) Monday said results from the pivotal Phase III Velour study evaluating Zaltrap showed improvement in overall survival rate to colorectal cancer.


- Sanofi said the Journal of Clinical Oncology published the results of the study evaluating Zaltrap effects.

- In the Velour trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the Folfiri chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus Folfiri.

- The Velour data supported the regulatory approval of Zaltrap by the U.S. Food and Drug Administration (FDA) on August 3, 2012 after a Priority Review.

- Zaltrap is under review at the European Medicines Agency and other regulatory agencies worldwide, Sanofi says.

-Write to Inti Landauro at

Subscribe to WSJ:

Stocks mentioned in the article : SANOFI
React to this article
Latest news on SANOFI
03:04p SANOFI : ImmunoGen skids after disclosing drug development setbacks
07:59aDJSanofi SA 1Q 2015-- Forecast
02:46a SANOFI : Added to National Access Project
04/24 KERYX BIOPHARMACEUTICALS : Change in Directors or Principal Officers (form 8-K)
04/24 SANOFI : Playing Safe With Your Food
04/24 GENZYME : Commences Phase 2a Clinical Trial to Evaluate Oral Therapy for Fabry D..
04/24 SANOFI : MILITARY $2.08 Million Federal Contract Awarded to Sanofi Pasteur
04/24 SANOFI : ImmunoGen Reports Third Quarter Fiscal Year 2015 Financial Results
04/23 SANOFI : Effect of Genzyme’s Multiple Sclerosis Treatment Lemtrada® (alemt..
04/23 SANOFI : Effect of Genzyme's Multiple Sclerosis Treatment Lemtrada® (alemtuzumab..
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes